XML 76 R65.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Commitments and Contingencies - Additional Information (Detail) € in Millions |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 48 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2023 USD ($) | Nov. 09, 2022 USD ($) | Jun. 02, 2022 USD ($) | Jul. 31, 2023 USD ($) | Jun. 30, 2023 USD ($) | Sep. 30, 2013 USD ($) | Apr. 30, 2013 USD ($) | Mar. 31, 2024 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2014 USD ($) | Aug. 21, 2022 USD ($) | Mar. 28, 2024 USD ($) | Aug. 21, 2023 USD ($) | Mar. 31, 2023 EUR (€) | Jul. 08, 2021 USD ($) | Aug. 31, 2019 USD ($) | Jul. 31, 2008 USD ($) | Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  | $ 700,000,000 |  |  |  |  |  |  |  |  | $ 350,000,000 |  |
Annual sales of Effexor |  |  |  |  |  |  |  |  |  |  |  | $ 2,600,000,000 |  |  |  |  |  |  |
Annual sales of Lamictal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,300,000,000 | $ 950,000,000
Annual sales of Niaspan |  |  |  |  |  | $ 1,100,000,000 | $ 416,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  |  |  | $ 4,250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  |  |  |  | 13 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Copaxone |  |  |  |  |  |  |  |  |  |  | $ 373,000,000 |  |  |  |  |  |  |  |
Generic modafinil, and imposed fines amount | $ 4,771,000,000 |  |  |  |  |  |  | 4,669,000,000 |  | $ 4,771,000,000 |  |  |  |  | € 60.5 |  |  |  |
Loss Contingency Accrual, Provision | 235,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of viread |  |  |  |  |  |  |  | 582,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of Truvada |  |  |  |  |  |  |  | 2,400,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of Atripla |  |  |  |  |  |  |  | 2,900,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of New launch of viread |  |  |  |  |  |  |  | 728,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of New launch of Truvada |  |  |  |  |  |  |  | 2,100,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of New launch of Atripla |  |  |  |  |  |  |  | 444,000,000 |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement Amount Distributable In Kind |  |  |  |  |  |  |  | 1,200,000,000 |  |  |  |  |  |  |  |  |  |  |
Accrual for Environmental Loss Contingencies |  |  |  |  |  |  |  | $ 300,000,000,000 |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies On Environmental Laws Penalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400,000 |  |  |
Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement |  |  |  |  |  |  |  | 99.00% |  |  |  |  |  |  |  |  |  |  |
Other commitment |  |  |  |  |  |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |  |
Annual Sales Of Revlimid |  |  |  |  |  |  |  | $ 3,500,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Share Of The National Population | 1.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentgae of amount in cash settlement |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement Amount Distributable in cash |  |  |  |  |  |  |  | $ 240,000,000 |  |  |  |  |  |  |  |  |  |  |
Loss Contingency, Damages Awarded, Value |  | $ 176,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
NEVADA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency, Settlement Agreement Terms |  |  |  |  | 20 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment |  |  |  |  | $ 193,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  | $ 1,000,000,000 |  |  |  |  |  |  |  |  |
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Donation of Clotrimazole and Tobramycin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other commitment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Fine for Violating the Antitrust Laws [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other commitment, to be paid, year five |  |  |  |  |  |  |  |  |  |  |  |  |  | 135,000,000 |  |  |  |  |
Other commitment to pay for each year |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,500,000 |  |  |  |  |
Other commitment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 225,000,000 |  |  |  |  |
Opioid Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year five |  |  |  |  |  |  |  | 393,000,000 |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year four |  |  |  |  |  |  |  | 374,000,000 |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year three |  |  |  |  |  |  |  | 368,000,000 |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year two |  |  |  |  |  |  |  | 364,000,000 |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year one |  |  |  |  |  |  |  | 418,000,000 |  |  |  |  |  |  |  |  |  |  |
Modafinil Settlement Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency aggregate payments paid |  |  |  |  |  |  |  | $ 74,000,000 |  |  |  |  |  |  |  |  |  |  |
Ontario Teachers Securities Litigation [Member] | Settled Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  | $ 420,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation With US Hospitals And Other Healthcare Providers [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  |  | $ 126,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  |  |  | 18 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product WAC Value |  |  |  | $ 49,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product WAC Term |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  | 200,000,000 |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |  |  |  |  |  |
AndroGel Rate at 1% [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 140,000,000 |  |

X
- Definition Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler. + References No definition available. + Details
Name: | teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales at time of settlement. + References No definition available. + Details
Name: | teva_AnnualSalesAtTimeOfSettlement
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual Sales Of Copaxone. + References No definition available. + Details
Name: | teva_AnnualSalesOfCopaxone
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of effexor. + References No definition available. + Details
Name: | teva_AnnualSalesOfEffexor
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Lamictal. + References No definition available. + Details
Name: | teva_AnnualSalesOfLamictal
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Annual sales of Niaspan. + References No definition available. + Details
Name: | teva_AnnualSalesOfNiaspan
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of revlimid. + References No definition available. + Details
Name: | teva_AnnualSalesOfRevlimid
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of new launch of Atripla. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of New launch of truvada. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of new launch of viread. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfViread
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of atripla. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfAtripla
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of truvada. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfTruvada
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of viread. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfViread
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitment And Contingencies [Line Items] + References No definition available. + Details
Name: | teva_CommitmentAndContingenciesLineItems
Namespace Prefix: | teva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation settlement amount awarded distribution period. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountAwardedDistributionPeriod
Namespace Prefix: | teva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation settlement amount distributable in cash. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountDistributableInCash
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount distributableIn kind. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountDistributableinKind
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount payable in cash percentage + References No definition available. + Details
Name: | teva_LitigationSettlementAmountPayableInCashPercentage
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss contingencies on environmental laws penalty. + References No definition available. + Details
Name: | teva_LossContingenciesOnEnvironmentalLawsPenalty
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency aggregate payments paid. + References No definition available. + Details
Name: | teva_LossContingencyAggregatePaymentsPaid
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency claims dismissed value paid to each state proportional to its share of national population + References No definition available. + Details
Name: | teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Other commitment to pay for each year. + References No definition available. + Details
Name: | teva_OtherCommitmentToPayForEachYear
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of share of the national population. + References No definition available. + Details
Name: | teva_PercentageOfShareOfTheNationalPopulation
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of the litigating subdivisions have chosen to participate in teva's nationwide settlement. + References No definition available. + Details
Name: | teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product weighted average cost. + References No definition available. + Details
Name: | teva_ProductWeightedAverageCost
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Product weighted average cost term. + References No definition available. + Details
Name: | teva_ProductWeightedAverageCostTerm
Namespace Prefix: | teva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total costs accrued as of the balance sheet date for environmental loss contingencies. + References Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481931/410-30-50-10 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481931/410-30-50-10 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481899/410-30-55-16 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481931/410-30-50-7 + Details
Name: | us-gaap_AccrualForEnvironmentalLossContingencies
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow reducing loss contingency liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingencyAccrualPayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFifthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFourthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInSecondYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInThirdYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueWithinOneYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingencyAccrualProvision
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencySettlementAgreementTerms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References No definition available. + Details
Name: | us-gaap_OtherCommitmentDueInFifthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_NV
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_AgreementAxis=teva_DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=teva_DonationOfClotrimazoleAndTobramycinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=teva_FineForViolatingTheAntitrustLawsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_OpioidLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_ModafinilSettlementAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_OntarioTeachersSecuritiesLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_LitigationWithUsHospitalsAndOtherHealthcareProvidersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |